SALT LAKE CITY

盐湖城

,

，

May 19, 2026

2026年5月19日

/PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq:

/PRNewswire/ -- Co-Diagnostics, Inc.（纳斯达克：

CODX

CODX

) ('Co-Dx', or the 'Company'), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into a securities purchase agreement with certain institutional investors to sell an aggregate of 1,647,447 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 3,294,894 shares of common stock, in a private placement priced at-the-market under Nasdaq rules (the 'Offering').

）（“Co-Dx”或“公司”），一家拥有独特且获得专利的分子诊断测试开发平台的分子诊断公司，今天宣布已与某些机构投资者签订了证券购买协议，将出售总计1,647,447股普通股（或替代的预融资认股权证），同时附带可购买总计3,294,894股普通股的认股权证，按纳斯达克规则以市价进行私人配售（“发行”）。

The combined effective offering price for each share of common stock (or pre-funded warrant in-lieu thereof) and accompanying warrants to be issued is $1.821. The warrants will have an exercise price of $1.571 per share, will be exercisable immediately upon issuance, and will expire five years from the date of issuance..

每股普通股（或代替其的预融资认股权证）及相关附带认股权证的合并有效发行价格为 1.821 美元。认股权证的行权价为每股 1.571 美元，将于发行后立即可行权，并在发行之日起五年后到期。

The gross proceeds to the Company from the Offering are estimated to be approximately $3.0 million before deducting the placement agent's fees and other estimated Offering expenses. The Offering is expected to close on or about May 21, 2026, subject to the satisfaction of customary closing conditions..

公司从此次发行中的总收益预计约为 300 万美元，在扣除配售代理费和其他预计发行费用之前。本次发行预计将于 2026 年 5 月 21 日左右完成，但需满足惯例的交割条件。

Maxim Group LLC is acting as the sole placement agent in connection with the Offering.

Maxim Group LLC 担任本次发行的唯一配售代理。

The offer and sale of the foregoing securities are being made in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Securities Act'), and/or Regulation D promulgated thereunder, and the securities have not been registered under the Securities Act or applicable state securities laws.

前述证券的要约和出售是根据经修订的《1933年证券法》（“证券法”）第4(a)(2)条及据此颁布的D条例进行的私募发行，且该等证券尚未根据证券法或适用的州证券法注册。

Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the securities purchased in the private placement..

因此，这些证券不得在美国重新发售或转售，除非根据有效的注册声明或《证券法》及适用的州证券法的注册要求的适用豁免。公司已同意向证券交易委员会提交一份注册声明，以注册在私募中购买的证券的转售。

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.

本新闻稿不构成出售证券的要约或购买证券的要约邀请，且在任何州内不得在未根据该州证券法进行注册或资格认定之前，进行此类要约、邀请或出售，因为这将是违法的。

Any offering of the securities under the resale registration statement will only be made by means of a prospectus..

根据转售登记声明进行的任何证券发售都只能通过招股说明书进行。

About Co-Diagnostics, Inc.

关于Co-Diagnostics公司

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease..

Co-Diagnostics, Inc.是一家犹他州公司，是一家分子诊断公司，致力于开发、制造和销售最先进的诊断技术。该公司的技术被用于设计检测和/或分析核酸分子（DNA或RNA）的测试。该公司还利用其专有技术为其Co-Dx PCR家用和即时护理平台（需经监管审查，目前尚未上市）设计特定测试，并识别用于传染性疾病以外应用的遗传标记。

Forward-Looking Statement

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the completion and timing of the Offering, the anticipated gross proceeds from the Offering, the intended use of proceeds, the filing of a resale registration statement, and other statements that are not historical facts.

本新闻稿包含1995年《私人证券诉讼改革法案》意义上的前瞻性陈述。前瞻性陈述包括但不限于关于本次发行的完成和时间安排、本次发行预期的总收益、收益的预期用途、转售登记声明的提交以及其他非历史事实的陈述。

Forward-looking statements may be identified by words such as 'anticipate,' 'believe,' 'expect,' 'intend,' 'plan,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'continue,' and similar expressions. These forward-looking statements are based on the Company's current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

前瞻性声明可以通过诸如“预期”、“相信”、“预计”、“打算”、“计划”、“潜力”、“将”、“可能”、“能够”、“应该”、“继续”等词语来识别。这些前瞻性声明基于公司当前的预期和假设，并受到许多可能导致实际结果与这些声明中明示或暗示的结果存在重大差异的风险和不确定性的影响。

These risks and uncertainties include, without limitation, risks and uncertainties related to satisfaction of customary closing conditions related to the Offering, market and other conditions, the timing and ability of the Company to file and have declared effective a resale registration statement, and other risks described from time to time in the Company's filings with the Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC.

这些风险和不确定性包括但不限于与发行相关的惯常交割条件的满足、市场及其他状况、公司提交并促使转售注册声明生效的时间和能力，以及公司在向证券交易委员会（“SEC”）提交的文件中不时描述的其他风险，包括公司向SEC提交的年度报告（表格10-K）和季度报告（表格10-Q）。

The forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements contained in this press release, except as required by applicable law..

本新闻稿中包含的前瞻性陈述仅截至本日期，公司不承担更新或修改本新闻稿中包含的任何前瞻性陈述的义务，除非适用法律要求。

SOURCE Co-Diagnostics

来源：Co-Diagnostics

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示